Ohcanbohtosat - Richárd Márkus
- Čájehuvvo 1 - 7 / 7
-
1
-
2
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab Dahkki Primal Kaur, Vincent Chow, Nan Zhang, Michael Moxness, Arunan Kaliyaperumal, Richárd Márkus
Almmustuhtton 2016Artigo -
3
-
4
-
5
Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial Dahkki Gabriela Senti, Bettina M. Prinz Vavricka, Iris Erdmann, Mella I. Diaz, Richárd Márkus, Stephen J. McCormack, John Simard, Brunello Wüthrich, Reto Crameri, Nicole Graf, Pål Johansen, Thomas M. Kündig
Almmustuhtton 2008Artigo -
6
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis Dahkki Ronald L. Gibson, George Retsch‐Bogart, Christopher M. Oermann, Carlos Milla, Joseph M. Pilewski, Cori Daines, Richard C. Ahrens, Kevin León, Morty Cohen, Sharon McNamara, Tracy L. Callahan, Richárd Márkus, Jane L. Burns
Almmustuhtton 2006Artigo -
7
NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives Dahkki Andrew D. Zelenetz, Islah Ahmed, Edward L. Braud, James D. Cross, Nancy Davenport-Ennis, Barry D. Dickinson, Steven E. Goldberg, Scott Gottlieb, Philip E. Johnson, Gary H. Lyman, Richárd Márkus, Ursula A. Matulonis, Denise K. Reinke, Edward C. Li, Jessica K. DeMartino, Jonathan K. Larsen, James M. Hoffman
Almmustuhtton 2011Artigo
Ohcanreaiddut:
Laktáseaddji fáttát
Internal medicine
Medicine
Pharmacology
Adverse effect
Gastroenterology
Biosimilar
Pharmacokinetics
Alternative medicine
Bioequivalence
Business
Cancer
Cmax
Geometry
Mathematics
Pathology
Product (mathematics)
Tolerability
Adalimumab
Allergen
Allergen immunotherapy
Allergy
Anesthesia
Anorexia
Antibiotic resistance
Antibiotics
Antibody
Aztreonam
Biology
Breast cancer
Cachexia